GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GlycoMimetics, Inc.

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with cancers and inflammatory diseases such as acute myeloid leukemia and sickle cell disease. Our mission is to improve outcomes for patients by advancing our research and clinical candidates, providing hope for patients as we strive to deliver breakthrough treatments. 
 
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies. Our leading researchers leverage their deep understanding of the role that carbohydrates play in cell recognition processes and use our proprietary chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. We harness our development and commercial expertise to move our wholly-owned drug candidates from research through late-stage clinical development.
 
We are a public company traded on the NASDAQ under the symbol GLYC.

Novartis Venture Fund

Alliance Technology Ventures

PTV Healthcare Capital

New Enterprise Associates

Anthem Capital Management

Sanofi Ventures

GlycoMimetics

Another important update regarding our GMI-1271 program in AML:  We completed enrollment of the second of two patient cohorts in the Phase 2 portion of our ongoing Phase 1/2 clinical trial. Read more.

GlycoMimetics, Inc., announced today the US FDA cleared addition of a time-based final analysis to its pivotal Phase 3 study in relapsed/refractory acute myeloid leukemia. Learn more: https://lnkd.in/efsUqaTm #GlycoMimetics #AML

Transformation is a marathon, not a sprint. Create a vision, explain the 'whys,' present unified messages and celebrate early wins. #transformation #glycomimetics

GlycoMimetics, Inc. released First Quarter 2023 results today. Our press release presents our financial results and corporate highlights for Q1 2023. bit.ly/44raQ7y

Today is AML World Awareness Day. Like every day, GlycoMimetics employees are working passionately to improve outcomes for people living with acute myeloid leukemia. #AML #KnowAML

GlycoMimetics, Inc. released Q4 and Year-End 2022 earnings results today. Our press release presents financials and our clinical and corporate highlights of the year.  #GlycoMimetics #earnings https://lnkd.in/dG9wWvfa

What does the future of leukemia treatment look like? GMI CEO Harout Semerjian shared his perspectives at a Cowen 43rd Annual Health Care Conference panel discussion.  https://lnkd.in/ePD_Nixr #TDCowen

We are thrilled Chinmaya Rath has joined GMI as SVP and Chief Business Officer! Chinmaya’s extensive pharma expertise, strategy acumen and passion for bringing new treatments to patients are highly valued as we prepare for our potential first commercial launch.

Welcome! Debora’s impressive history of 17+ successful therapeutic product launches, including in hematology, makes her very well-suited to build our commercial capabilities.

COM:GLYCOMIMETICS